nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2017-4-2-78-84nodgo-297Research ArticleОригинальные исследованияКлиническое значение полиморфизма гена тиопуринметилтрансферазы у детей с острым лимфобластным лейкозом при проведении программной терапииClinical significance of polymorphism of thiopurine methyltransferase gene in children with acute lymphoblastic leukemia during programmed therapyПетинаО. В.PetinaO. V.

223053 Минский район, дер. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk region 223053

o.vpetina@mail.ruЗборовскаяА. А.ZborovskayaA. A.

223053 Минский район, дер. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk region 223053

МатевосянМ. Л.MatevosyanM. L.

223053 Минский район, дер. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk region 223053

СавицкаяТ. В.SavitskayaT. V.

223053 Минский район, дер. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk region 223053

АлейниковаО. В.AleynikovaO. V.

223053 Минский район, дер. Боровляны, ул. Фрунзенская, 43

43 Frunzenskaya St., Borovlyany village, Minsk region 223053

ГУ «Республиканский научно-практический центр детской онкологии, гематологии и иммунологии» Министерства здравоохранения Республики БеларусьБеларусьRepublican Center for Pediatric Oncology, Hematology and ImmunologyBelarus201716062017427884Copyright © Петина О.В., Зборовская А.А., Матевосян М.Л., Савицкая Т.В., Алейникова О.В., 20172017Петина О.В., Зборовская А.А., Матевосян М.Л., Савицкая Т.В., Алейникова О.В.Petina O.V., Zborovskaya A.A., Matevosyan M.L., Savitskaya T.V., Aleynikova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/297

Представлены данные оценки генетического полиморфизма тиопуринметилтрансферазы (Thiopurine S-methyltransferase, ТРМТ) у 97 детей разного возраста, больных острым лимфобластным лейкозом (ОЛЛ). Полученные частотные характеристики встречаемости генотипов ТРМТ: *1 – 90,7 %, *3A – 8,3 %, *3C – 1,0 % сопоставимы с опубликованными литературными данными. При анализе связи генетического полиморфизма ТРМТ с токсичностью проводимого лечения по протоколу ALL-MB-2002 установлено достоверное преобладание тяжелой гематологической токсичности у гетерозиготных носителей мутантных аллелей в сравнении с носителями «дикого» типа. Установлено увеличение длительности тяжелой нейтропении на этапах консолидации при генетическом полиморфизме ТРМТ. Генетический полиморфизм ТРМТ не ухудшал результаты терапии ОЛЛ. Выявлена связь генетического полиморфизма ТРМТ с развитием второй опухоли.

Data on estimation of genetic polymorphism thiopurine methyltransferase (ТРМТ) at 97 children of different ages with acute lymphoblastic leukemia (ALL) presented. Studied frequency characteristics of TPMT genotypes: *1 – 90.7 %, *3A – 8.3 %, *3C – 1.0 % comparable with published data. During the analysis of connection of genetic polymorphism TPMT c toxicity of treatment on ALL-MB-2002 protocol it was established significant predominance of severe hematological toxicity at heterozygous patients with mutant alleles in comparison with “wild type” patients. Increasing of severe neutropenia on consolidation stages showed in case of genetic polymorphism of TPMT. Genetic polymorphism did not affect results of ALL treatment. Correlation between TPMT polymorphism and second cancer established.

генетический полиморфизмострый лимфобластный лейкоздетипрограммная терапиягематологическая токсичностьgenetic polymorphismacute lymphoblastic leukemiachildrenprogram therapyhematological toxicityReferencesSchrappe M., Camitta B., Pui C-H. et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000;14:2193–4.Schrappe M., Camitta B., Pui C-H. et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 2000;14:2193–4.Карачунский А.И., Румянцев А.Г., Штакельберг А. и др. Сравнение протоколов ALL-BFM-90 и ALL-MB-91 для лечения острого лимфобластного лейкоза у детей (предварительные результаты). Педиатрия. Журнал им. Г.Н. Сперанского 1995;2:10–4. [Karachunskiy A.I., Rumyantsev A.G., Shtakelberg A. et al. Comparison of the protocols ALL-BFM-90 and ALL-MB-91 for the treatment of acute lymphoblastic leukemia in children (preliminary results). Pediatria = Pediatrics. Journal named after G.N. Speransky 1995;2:10–4. (In Russ.)].Карачунский А.И., Румянцев А.Г., Штакельберг А. и др. Сравнение протоколов ALL-BFM-90 и ALL-MB-91 для лечения острого лимфобластного лейкоза у детей (предварительные результаты). Педиатрия. Журнал им. Г.Н. Сперанского 1995;2:10–4. [Karachunskiy A.I., Rumyantsev A.G., Shtakelberg A. et al. Comparison of the protocols ALL-BFM-90 and ALL-MB-91 for the treatment of acute lymphoblastic leukemia in children (preliminary results). Pediatria = Pediatrics. Journal named after G.N. Speransky 1995;2:10–4. (In Russ.)].Карачунский А.И., Мякова Н.В., Румянцева Ю.В. и др. Результаты мультицентрового исследования лечения острого лимфобластного лейкоза у детей по программам ALL-MB-91/ALL-BFM-90m: анализ эффективности и токсичности. Терапевтический архив 2007;79(7):19–26. [Karachunskiy A.I., Myakova N.V., Rumyantseva Yu.V. et al. The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB91/ALL-BFM90m in children: analysis of efficacy and toxicity. Terapevticheskiy arhiv = Therapeutic archive 2007;79(7):19–26. (In Russ.)].Карачунский А.И., Мякова Н.В., Румянцева Ю.В. и др. Результаты мультицентрового исследования лечения острого лимфобластного лейкоза у детей по программам ALL-MB-91/ALL-BFM-90m: анализ эффективности и токсичности. Терапевтический архив 2007;79(7):19–26. [Karachunskiy A.I., Myakova N.V., Rumyantseva Yu.V. et al. The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL-MB91/ALL-BFM90m in children: analysis of efficacy and toxicity. Terapevticheskiy arhiv = Therapeutic archive 2007;79(7):19–26. (In Russ.)].Karachunskiy A., Herold R., von Stackelberg A. et al. Results of the first randomized multicentre trial in chidhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22(6):1144–53.Karachunskiy A., Herold R., von Stackelberg A. et al. Results of the first randomized multicentre trial in chidhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22(6):1144–53.Блохина Е.Б. Роль генетического полиморфизма в онкологии. Качественная клиническая практика 2004;1:2–5. [Blokhina E.B. The role of genetic polymorphism in oncology. Kachestvennaya klinicheskaya praktika = Qualitative clinical practice 2004;1:2–5. (In Russ.)].Блохина Е.Б. Роль генетического полиморфизма в онкологии. Качественная клиническая практика 2004;1:2–5. [Blokhina E.B. The role of genetic polymorphism in oncology. Kachestvennaya klinicheskaya praktika = Qualitative clinical practice 2004;1:2–5. (In Russ.)].Румянцева Ю.В., Карачунский А.И., Румянцев А.Г. Оптимизация терапии острого лимфобластного лейкоза у детей в России. Педиатрия 2009;87(4):19–27. [Rumyantseva Yu.V., Karachunskiy A.I., Rumyantsev A.G. Optimization of acute lymphoblastic leukemia therapy in children in Russia. Pediatria = Pediatrics. Journal named after G.N. Speransky 2009;87(4): 19–27. (In Russ.)].Румянцева Ю.В., Карачунский А.И., Румянцев А.Г. Оптимизация терапии острого лимфобластного лейкоза у детей в России. Педиатрия 2009;87(4):19–27. [Rumyantseva Yu.V., Karachunskiy A.I., Rumyantsev A.G. Optimization of acute lymphoblastic leukemia therapy in children in Russia. Pediatria = Pediatrics. Journal named after G.N. Speransky 2009;87(4): 19–27. (In Russ.)].Krynetski E.Y., Schuetz J.D., Calpin A.J. et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995;92:949–53.Krynetski E.Y., Schuetz J.D., Calpin A.J. et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995;92:949–53.Samochatova E.V., Chupovа N.V., Rudneva A. et al. TPMT genetic variations in populations of the Russian Federation. Pediatr Blood Cancer 2009;52(2):203–8.Samochatova E.V., Chupovа N.V., Rudneva A. et al. TPMT genetic variations in populations of the Russian Federation. Pediatr Blood Cancer 2009;52(2):203–8.Yates C.R., Krynetski E.Y., Loennechen T. et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608.Yates C.R., Krynetski E.Y., Loennechen T. et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608.Schaeffeler E., Fischer C., Brockmeier D. et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German- Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14:407.Schaeffeler E., Fischer C., Brockmeier D. et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German- Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004;14:407.Coulthard S.A., Howell C., Robson J., Hall A.G. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 1998;92(8):2856–62.Coulthard S.A., Howell C., Robson J., Hall A.G. The relationship between thiopurine methyltransferase activity and genotype in blasts from patients with acute leukemia. Blood 1998;92(8):2856–62.McLeod H.L., Coulthard S., Thomas A.E. et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105:696–700.McLeod H.L., Coulthard S., Thomas A.E. et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105:696–700.Чупова Н.В., Самочатова Е.В., Руднева А.Е. и др. Генетический полиморфизм тиопурин-S-метилтрансферазы в лечении детей с острым лимфобластным лейкозом. Гематология и трансфузиология 2005;50(60):3–9. [Chupova N.У., Samochatova Е.V., Rudneva A.E. et al. Genetic polymorphism of thiopurine-S-methyltransferase and treatment of childhood acute lymphoblastic leukemia. Gematologiya i Transfusiologiya = Hematology and Transfusiology 2005;50(60):3–9. (In Russ.)].Чупова Н.В., Самочатова Е.В., Руднева А.Е. и др. Генетический полиморфизм тиопурин-S-метилтрансферазы в лечении детей с острым лимфобластным лейкозом. Гематология и трансфузиология 2005;50(60):3–9. [Chupova N.У., Samochatova Е.V., Rudneva A.E. et al. Genetic polymorphism of thiopurine-S-methyltransferase and treatment of childhood acute lymphoblastic leukemia. Gematologiya i Transfusiologiya = Hematology and Transfusiology 2005;50(60):3–9. (In Russ.)].Relling M.V., Hancock M.L., Rivera G.K. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001–08.Relling M.V., Hancock M.L., Rivera G.K. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001–08.Eloualid A., Abidi O., Charif M. et al. Association of the MTHFR A1298C variant with unexplained severe male infertility. PLoS One 2012;7(3):e34111.Eloualid A., Abidi O., Charif M. et al. Association of the MTHFR A1298C variant with unexplained severe male infertility. PLoS One 2012;7(3):e34111.Matsuo K., Hamajima N., Hirai T. et al. Methionine Synthase Reductase Gene A66G Polymorphism is Associated with Risk of Colorectal Cancer. Asian Pac J Cancer Prev 2002;3(4):353–9.Matsuo K., Hamajima N., Hirai T. et al. Methionine Synthase Reductase Gene A66G Polymorphism is Associated with Risk of Colorectal Cancer. Asian Pac J Cancer Prev 2002;3(4):353–9.Leufkens H.G. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol 2000;410:121.Leufkens H.G. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol 2000;410:121.Wang L., McLeod H.L., Weinshilboum R.M. Genomics and drug response. N Engl J Med 2011;364:1144.Wang L., McLeod H.L., Weinshilboum R.M. Genomics and drug response. N Engl J Med 2011;364:1144.Vesell E.S. Therapeutic lessons from pharmacogenetics. Ann Intern Med 1997;126:653.Vesell E.S. Therapeutic lessons from pharmacogenetics. Ann Intern Med 1997;126:653.Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487.Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487.Mancinelli L., Cronin M., Sadée W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci 2000;2(1):E4.Mancinelli L., Cronin M., Sadée W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci 2000;2(1):E4.Andersen J.B., Szumlanski C., Weinshilboum R.M. et al. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998;87:108.Andersen J.B., Szumlanski C., Weinshilboum R.M. et al. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998;87:108.Evans W.E., Horner M., Chu Y.Q. et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985.Evans W.E., Horner M., Chu Y.Q. et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985.Lennard L., Van Loon J.A., Weinshilboum R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149.Lennard L., Van Loon J.A., Weinshilboum R.M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149.Zelinkova Z., Derijks L.J., Stokkers P.C. et al. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006;4:44.Zelinkova Z., Derijks L.J., Stokkers P.C. et al. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 2006;4:44.Evans W.E., Hon Y.Y., Bomgaars L. et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-301.Evans W.E., Hon Y.Y., Bomgaars L. et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-301.Krynetski E.Y., Tai H.L., Yates C.R. et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996;6:279.Krynetski E.Y., Tai H.L., Yates C.R. et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996;6:279.McLeod H.L., Lin J.S., Scott E.P. et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15.McLeod H.L., Lin J.S., Scott E.P. et al. Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15.Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9.Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001;2:9.

The authors declare that there are no conflicts of interest present.